ArticleJournal of thoracic disease2023
Serum iron status and the risk of lung cancer: a two-sample Mendelian-randomization study.
Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Development and validation of a prognosis prediction model for overall survival in correlation between butyrate metabolism and gastric cancer prognosis: Mendelian randomization and transcriptomics analysis.Translational cancer research · 2025Article
- The causal role of immune cells on lung cancer: a bi-directional Mendelian randomization (MR) study.Aging · 2024Article
- Iron and cancer: overview of the evidence from population-based studies.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous epidemiological studies have reported controversial findings about the potential causal association between iron status and lung cancer. This study sought to assess the potential causality of serum iron status and lung cancer using the Mendelian-randomization (MR) method. Methods: We selected the genetic variables for iron status from the Genetics of Iron Status (GIS) consortium comprising 48,972 samples from European populations. The following two analysis strategies for instrumental variables (IVs) were applied: a conservative approach (instruments related to four iron status markers), and a liberal approach (instruments related to each iron status marker). The summary-level data for lung cancer were obtained from the International Lung Cancer Consortium comprising 27,209 individuals from European populations. The causality between serum iron status and lung cancer was examined. Results: Using the conservative approach, a higher serum iron status was found to be causally correlated with lower risks of lung squamous cell carcinoma. The odds ratios of lung squamous cell carcinoma per standard deviation (SD) unit increment in the four iron status markers were 0.73 [95% confidence interval (CI): 0.60-0.89; P=0.002] in serum iron, 0.50 (95% CI: 0.33-0.77; P=0.002) in ferritin, 1.35 (95% CI: 1.09-1.67; P=0.006) in transferrin, and 0.80 (95% CI: 0.69-0.92; P=0.001) in transferrin saturation based on the inverse variance-weighted method. Similar results were found using the liberal approach. Conclusions: Genetically, a high serum iron status was inversely associated with the risk of lung squamous cell carcinoma. More research needs to be conducted to explore the underlying mechanisms and to determine the potential application value about preventing the occurrence of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.